BCM
APLS

BlueCrest Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

BlueCrest Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-12,600
Closed -$224K – 859
2018
Q3 		$224K Buy
+12,600
New +$233K 0.01% 1211

Other funds holding APLS

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlueCrest Capital Management's APLS Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q4 2018, closing a stake of 12,600 shares — an estimated $224K sold.

BlueCrest Capital Management first reported a position in APLS in Q3 2018 and held it in 1 quarter. The position peaked at $224K in Q3 2018. 95 funds tracked by Wall St. Rank hold APLS as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Apellis Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 12,600 Apellis Pharmaceuticals shares in Q4 2018, an estimated $224K.
  • BlueCrest Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Apellis Pharmaceuticals position peaked at $224K in Q3 2018.
  • 95 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.